Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for VX-680 (compound)
Most Correlated Studies
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Most Relevant Literature
- Aurora kinase inhibitor VX-680 enhances sensitivity of esophageal squamous cell carcinoma cells to c…
- Aurora kinase inhibitor VX‑680 suppresses the proliferation and migration of HUVECs and angiogenesis…
- Interaction of novel Aurora kinase inhibitor MK-0457 with human serum albumin: Insights into the dyn…
- VX-680 induces p53-mediated apoptosis in human cholangiocarcinoma cells.
- The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.
Most Relevant Clinical Trials
- A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)
- Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or …
- MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Adva…
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Ol…
- TreatmENT of AnastomotiC Leakage After Esophagectomy
